Dec 15 2025
Discussion of Phase I Data on a Unique anti-VWF Thrombolytic
A summary by Dr. Wolfgang Miesbach: A potential landmark thrombolytic innovation presented at ASH 2025. Thrilled by the exciting Phase 1 data presentation by Marie Scully and co-authors on TGD001, a groundbreaking novel von Willebrand factor (VWF)-targeting thrombolytic: First-of-its-kind mechanism: TGD001 is an antibody-enzyme fusion protein—specifically, an anti-VWF antibody fragment fused to a urokinase catalytic domain. […]
read more